These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1298037)

  • 21. Salmon calcitonin: state of the art in prevention of postmenopausal bone loss?
    Reginster JY; Deroisy R; Denis D; Lecart MP; Franchimont P
    Acta Belg Med Phys; 1989; 12(2):41-6. PubMed ID: 2690544
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical management of osteoporosis.
    Mulloy AL; Weinstein RS
    J Med Assoc Ga; 1994 Apr; 83(4):227-30. PubMed ID: 8006552
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparison of calcitonin tolerance after intramuscular or intranasal administration in treatment for postmenopausal osteoporosis].
    Horst-Sikorska W; Ruszkowska J; Kosowicz J
    Przegl Lek; 1996; 53(1):9-11. PubMed ID: 8711177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term local tolerability to intranasally administered salmon calcitonin in post-menopausal osteoporosis].
    Gariboldi LM; Bolla I; Baroni MC; Delsignore R; Passeri M; Barberis F
    Minerva Med; 1992 Dec; 83(12):827-31. PubMed ID: 1491763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nasal calcitonin.
    Silverman SL
    Endocrine; 1997 Apr; 6(2):199-202. PubMed ID: 9225136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcitonin reserve and the differentiated response to calcitonin in osteoporosis.
    Vlăduţiu T; Lopez A; Gozariu L; Barabaş E
    Endocrinologie; 1990; 28(3-4):139-47. PubMed ID: 2103972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
    J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination].
    Szücs J; Horváth C; Kollin E; Szathmári M; Holló I
    Orv Hetil; 1992 Jun; 133(23):1415-8. PubMed ID: 1603585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis.
    Hizmetli S; Elden H; Kaptanoglu E; Nacitarhan V; Kocagil S
    Int J Clin Pract; 1998 Oct; 52(7):453-5. PubMed ID: 10622084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Early therapy of osteoporosis with (1-38) parathyroid hormone and calcitonin nasal spray].
    Hesch RD; Rittinghaus EF; Harms HM; Delling G
    Med Klin (Munich); 1989 Oct; 84(10):488-98. PubMed ID: 2685534
    [No Abstract]   [Full Text] [Related]  

  • 32. Calcitonin and the treatment of osteoporosis.
    Schneyer CR
    Md Med J; 1991 Jun; 40(6):469-73. PubMed ID: 1861574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
    Campusano C; López JM; Campino C; Cárdenas I; Rojas A
    Rev Med Chil; 2000 Apr; 128(4):387-91. PubMed ID: 10962855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of salcatonin given intranasally on early postmenopausal bone loss.
    Overgaard K; Riis BJ; Christiansen C; Hansen MA
    BMJ; 1989 Aug; 299(6697):477-9. PubMed ID: 2507027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
    van der Wiel HE; Lips P; Nauta J; Kwakkel G; Hazenberg G; Netelenbos JC; van der Vijgh WJ
    J Bone Miner Res; 1993 Dec; 8(12):1459-65. PubMed ID: 8304047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate in the treatment of osteoporosis.
    Adami S
    Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215
    [No Abstract]   [Full Text] [Related]  

  • 37. [PROOF study(calcitonin)].
    Hagino H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():450-4. PubMed ID: 15035169
    [No Abstract]   [Full Text] [Related]  

  • 38. Calcitonin nasal spray in patients with chronic asthma: a double-blind crossover study vs placebo.
    Dal Negro R; Turco P; Pomari C; Trevisan F
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):144-6. PubMed ID: 2071263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal complications in women with osteoporosis under treatment with nasal calcitonin spray: case reports and review of the literature.
    Chatziavramidis A; Mantsopoulos K; Gennadiou D; Sidiras T
    Auris Nasus Larynx; 2008 Sep; 35(3):417-22. PubMed ID: 18053666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Calcitonin].
    Nakano T
    Clin Calcium; 2008 Oct; 18(10):1460-8. PubMed ID: 18830043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.